Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs

Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.”

The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes:
 A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.
 A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.
 Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).
 An analysis of the partnerships that have been established in this domain, in the recent past.
 An analysis of the various expansion initiatives undertaken by the players in this domain.
 An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.
 A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.
 A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.
 A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 Type of Product
 HPAPIs
 Highly Potent Finished Dosage Forms

 Company Size
 Small-sized
 Mid-sized
 Large / Very Large

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Type of Pharmacological Molec

Leave a Reply

Your email address will not be published. Required fields are marked *

Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs

 Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing services for HPAPIs and cytotoxicdrugs
 The market is fragmented, featuring the presence of both established players and new entrants based in different geographies that claim to be capable of manufacturing highly potent products, at varying scales of operation
 In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies offering services across different scales of operation have established presence in various geographical regions
 In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to highly potent drug products
 In order to enhance the core competencies in this domain, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities
 Most of the installed, global HPAPI and cytotoxic drug manufacturing capacity belongs to established CMOs, accounting for close to 75% of the available capacity across various geographies
 Case-in-point: ADCs represent a significant growth opportunity; over 30 CMOs currently extend their services to manufacture one or multiple components of an ADC molecule

To request for Sample Report – https://www.rootsanalysis.com/reports/299/request-sample.html

 We expect highly potent drug developers to continue to outsource their manufacturing operations in the mid to long term, causing service-based revenues to grow at an annualized rate of more than 10%
 In the long-term, the projected opportunity for the contract manufacturing of HPAPIs and cytotoxic drugs is likely to be well distributed across various dosage forms, nature of molecules and sizes of contract service providers
For more information, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

Tabl

Leave a Reply

Your email address will not be published. Required fields are marked *